Condition (MeSH)
Leishmaniasis, Cutaneous
ClinicalTrials.gov lists 113 trials for Leishmaniasis, Cutaneous or a narrower condition beneath it. U.S. Army Medical Research and Development Command has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
102 of the 113 trials are tagged with Leishmaniasis, Cutaneous itself; the rest are tagged with a narrower condition beneath it.
When did Leishmaniasis, Cutaneous trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 7 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 7 |
| 2020 | 3 |
| 2019 | 8 |
| 2018 | 2 |
| 2017 | 5 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 28 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 73 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leishmaniasis, Cutaneous trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 4 |
| Phase 2 | 33 |
| Phase 2/3 | 9 |
| Phase 3 | 19 |
| Phase 4 | 4 |
| Not applicable | 11 |
| Observational | 22 |
| Expanded access | 3 |
How many Leishmaniasis, Cutaneous trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 10 |
| Active, not recruiting | 1 |
| Available | 1 |
| Completed | 70 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leishmaniasis, Cutaneous trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| U.S. Army Medical Research and Development Command | 12 |
| Knight Therapeutics (USA) Inc | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
Which drugs are being tested for Leishmaniasis, Cutaneous? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Meglumine Antimoniate | 18 |
| Miltefosine | 17 |
| Paromomycin | 4 |
| Pentoxifylline | 3 |
| SB3 | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| WR 279,396 | 6 |
| Sodium Stibogluconate | 6 |
| Leish-111f + MPL-SE vaccine | 4 |
| liposomal Amphotericine B | 4 |
| data collection | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Leishmaniasis, Cutaneous trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendectomy | 2 | 1 |
| Death in combat | 2 | 1 |
| Accute gastroenteritis | 1 | 1 |
| Arm fracture | 1 | 1 |
| Basal cell carcinoma, superficial | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Leishmaniasis, Cutaneous? (151)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 151 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.